203 related articles for article (PubMed ID: 35705564)
1. Cysteamine exerts in vitro antiviral activity against the SARS-CoV-2 Delta and Omicron variants.
Alonzi T; Aiello A; Repele F; Falasca L; Francalancia M; Garbuglia AR; Delogu G; Nicastri E; Piacentini M; Goletti D
Cell Death Discov; 2022 Jun; 8(1):288. PubMed ID: 35705564
[TBL] [Abstract][Full Text] [Related]
2. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D
Cells; 2021 Dec; 11(1):. PubMed ID: 35011614
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of cysteamine against SARS-CoV-2 variants.
Thoene J; Gavin RF; Towne A; Wattay L; Ferrari MG; Navarrete J; Pal R
Mol Genet Metab; 2022; 137(1-2):192-200. PubMed ID: 36115282
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells.
Zhao H; Lu L; Peng Z; Chen LL; Meng X; Zhang C; Ip JD; Chan WM; Chu AW; Chan KH; Jin DY; Chen H; Yuen KY; To KK
Emerg Microbes Infect; 2022 Dec; 11(1):277-283. PubMed ID: 34951565
[TBL] [Abstract][Full Text] [Related]
5. Drastic decline in sera neutralization against SARS-CoV-2 Omicron variant in Wuhan COVID-19 convalescents.
Ma C; Chen X; Mei F; Xiong Q; Liu Q; Dong L; Liu C; Zou W; Zhan F; Hu B; Liu Y; Liu F; Zhou L; Xu J; Jiang Y; Xu K; Cai K; Chen Y; Yan H; Lan K
Emerg Microbes Infect; 2022 Dec; 11(1):567-572. PubMed ID: 35060426
[TBL] [Abstract][Full Text] [Related]
6. The Omicron variant BA.1.1 presents a lower pathogenicity than B.1 D614G and Delta variants in a feline model of SARS-CoV-2 infection.
Martins M; do Nascimento GM; Nooruzzaman M; Yuan F; Chen C; Caserta LC; Miller AD; Whittaker GR; Fang Y; Diel DG
bioRxiv; 2022 Jun; ():. PubMed ID: 35734088
[TBL] [Abstract][Full Text] [Related]
7. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant.
Schubert M; Bertoglio F; Steinke S; Heine PA; Ynga-Durand MA; Maass H; Sammartino JC; Cassaniti I; Zuo F; Du L; Korn J; Milošević M; Wenzel EV; Krstanović F; Polten S; Pribanić-Matešić M; Brizić I; Baldanti F; Hammarström L; Dübel S; Šustić A; Marcotte H; Strengert M; Protić A; Piralla A; Pan-Hammarström Q; Čičin-Šain L; Hust M
BMC Med; 2022 Mar; 20(1):102. PubMed ID: 35236358
[TBL] [Abstract][Full Text] [Related]
8. Analysis of SARS-CoV-2 isolates, namely the Wuhan strain, Delta variant, and Omicron variant, identifies differential immune profiles.
Shahbaz S; Bozorgmehr N; Lu J; Osman M; Sligl W; Tyrrell DL; Elahi S
Microbiol Spectr; 2023 Sep; 11(5):e0125623. PubMed ID: 37676005
[TBL] [Abstract][Full Text] [Related]
9. Minimal Crossover between Mutations Associated with Omicron Variant of SARS-CoV-2 and CD8
Redd AD; Nardin A; Kared H; Bloch EM; Abel B; Pekosz A; Laeyendecker O; Fehlings M; Quinn TC; Tobian AAR
mBio; 2022 Apr; 13(2):e0361721. PubMed ID: 35229637
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective.
Saxena SK; Kumar S; Ansari S; Paweska JT; Maurya VK; Tripathi AK; Abdel-Moneim AS
J Med Virol; 2022 Apr; 94(4):1738-1744. PubMed ID: 34905235
[TBL] [Abstract][Full Text] [Related]
11. Antiviral Activity of Repurposing Ivermectin against a Panel of 30 Clinical SARS-CoV-2 Strains Belonging to 14 Variants.
Delandre O; Gendrot M; Jardot P; Le Bideau M; Boxberger M; Boschi C; Fonta I; Mosnier J; Hutter S; Levasseur A; La Scola B; Pradines B
Pharmaceuticals (Basel); 2022 Apr; 15(4):. PubMed ID: 35455442
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of the SARS-CoV-2 Omicron (B.1.1.529) Variant and Emerging Impact on Global Public Health.
Rabiul Islam M; Nasreen W; Anjum R; Shahriar M; Roy A; Dhama K; Ahmed Bhuiyan M
Clin Pathol; 2022; 15():2632010X221124908. PubMed ID: 36147794
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 Omicron Induces Enhanced Mucosal Interferon Response Compared to other Variants of Concern, Associated with Restricted Replication in Human Lung Tissues.
Alfi O; Hamdan M; Wald O; Yakirevitch A; Wandel O; Oiknine-Djian E; Gvili B; Knoller H; Rozendorn N; Golan Berman H; Adar S; Vorontsov O; Mandelboim M; Zakay-Rones Z; Oberbaum M; Panet A; Wolf DG
Viruses; 2022 Jul; 14(7):. PubMed ID: 35891570
[TBL] [Abstract][Full Text] [Related]
14. Replication kinetics and infectivity of SARS-CoV-2 variants of concern in common cell culture models.
Mautner L; Hoyos M; Dangel A; Berger C; Ehrhardt A; Baiker A
Virol J; 2022 Apr; 19(1):76. PubMed ID: 35473640
[TBL] [Abstract][Full Text] [Related]
15. Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination.
Silva ARD; Villas-Boas LS; Tozetto-Mendoza TR; Honorato L; Paula A; Witkin SS; Mendes-Correa MC
Rev Inst Med Trop Sao Paulo; 2022; 64():e19. PubMed ID: 35239863
[TBL] [Abstract][Full Text] [Related]
16. The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron.
Zhang L; Li Q; Liang Z; Li T; Liu S; Cui Q; Nie J; Wu Q; Qu X; Huang W; Wang Y
Emerg Microbes Infect; 2022 Dec; 11(1):1-5. PubMed ID: 34890524
[TBL] [Abstract][Full Text] [Related]
17. Pathogenicity of SARS-CoV-2 Omicron (R346K) variant in Syrian hamsters and its cross-neutralization with different variants of concern.
Mohandas S; Yadav PD; Sapkal G; Shete AM; Deshpande G; Nyayanit DA; Patil D; Kadam M; Kumar A; Mote C; Jain R
EBioMedicine; 2022 May; 79():103997. PubMed ID: 35405385
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo.
Hui KPY; Ho JCW; Cheung MC; Ng KC; Ching RHH; Lai KL; Kam TT; Gu H; Sit KY; Hsin MKY; Au TWK; Poon LLM; Peiris M; Nicholls JM; Chan MCW
Nature; 2022 Mar; 603(7902):715-720. PubMed ID: 35104836
[TBL] [Abstract][Full Text] [Related]
19. 1,2,3-Triazole-Benzofused Molecular Conjugates as Potential Antiviral Agents against SARS-CoV-2 Virus Variants.
Al-Humaidi JY; Shaaban MM; Rezki N; Aouad MR; Zakaria M; Jaremko M; Hagar M; Elwakil BH
Life (Basel); 2022 Aug; 12(9):. PubMed ID: 36143380
[TBL] [Abstract][Full Text] [Related]
20. Survivability of Delta and Omicron variants of SARS-CoV-2 in wastewater.
Sherchan SP; Thakali O; Ikner LA; Gerba C; Haramoto E
Water Res; 2023 Nov; 246():120644. PubMed ID: 37844338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
